3DBioFibR develops scalable biopolymer fibers using a patented dry‑spinning platform that can process over six biopolymers. Its fibers report performance metrics two to three times the strength of natural tissue and are produced at over 3,600× the scale of conventional wet spinning and electrospinning, with improved uniformity and cost‑efficiency. The company has signed paid development agreements and partnerships across tissue engineering, medical devices, defense, cosmetics, and apparel, including several multinational corporations. The recently closed financing will fund ISO 13485 certification, construction of a clean room, and manufacturing scale‑up to meet rising global demand for medical‑grade and performance biomaterials. 3DBioFibR positions itself as a supplier for regulated clinical and therapeutic applications and plans to expand commercial and clinical partnerships. The company is based in Halifax, Nova Scotia. 3D BioFibR develops patented, fully automated collagen-fiber manufacturing technology to produce biofibres that mimic natural materials such as spider silk and collagen. The company is focused on producing recombinant human collagen for the medical research market and launched two products in June: μCollaFibR and CollaFibR, a three-dimensional cell-culture scaffold. To scale production the firm is collaborating with PlantForm Corporation and plans to use PlantForm’s vivoXPRESS plant-based biologics platform rather than mammalian-cell systems. A recent collaborative project funded by Next Generation Manufacturing Canada aims to improve collagen expression scale, increase fiber manufacturing capacity, and validate methods for incorporating recombinant collagen feedstock. 3D BioFibR was founded in 2020 by Sullivan and CSO John Frampton, a biomedical engineering professor at Dalhousie University, and operates with a 12-person team. Financially, the company previously raised $550,000 in 2020 and $700,000 of equity in 2021, and closed an equity and debt round worth $3.52 million in July of this year. 3D BioFibR develops and produces high-value collagen fibers at commercial scale using a proprietary, fully automated dry-spinning process. The company says its process is the only one that produces diameter-controlled collagen fibers at commercial scale and is at least 3,600x faster than competing manufacturing methods. Its collagen fibers are positioned for use in 3D cell culture and tissue engineering, recreating the natural appearance, structure, and function of collagen. 3D BioFibR plans to expand facilities to include a climate-controlled biomanufacturing cleanroom and a new wet lab and cell culture facility to bring its premium collagen fiber products to market. The company is backed by seed financing and receiving government support, including a repayable contribution and NRC IRAP advisory and R&D funding to support development of an automated collagen fiber manufacturing system. Management emphasizes accelerating capacity to meet growing demand from tissue engineers. 3D BioFibR produces naturally sourced, high-value biofibers including collagen (CollaFibR™) and spider silk for use in biomedical engineering, 3D tissue culture, tissue engineering, green textiles, defense, and aerospace. The company uses a proprietary dry-spinning manufacturing process that the team says is faster than current methods and preserves the natural properties of the proteins. Recent messaging emphasizes transition from a lab-based process to an automated production system to deliver consistent, high-quality products at commercial scale. Management plans to scale up and automate manufacturing to be ready for first market sales in the second half of 2022. The company is prioritizing engagement with industry to secure commercial partnerships, with an initial focus on tissue culture and tissue engineering applications. 3D BioFibR was incorporated in July 2020 and is operating from Halifax, Nova Scotia. 3D BioFibR is an advanced biofibre materials company based in Halifax, Nova Scotia, Canada. It manufactures naturally sourced, high-value biofibres including spider silk, collagen and chitosan. The company targets applications across biomedical engineering, green textiles, defense and aerospace. Leadership includes CEO Kevin Sullivan and Chief Scientific Officer Dr. John Frampton. 3D BioFibR plans to use new capital to develop and commercialize its tissue engineering and biomedical device products and to scale up manufacturing of its biofibre platform. The firm raised external funding to support those development and commercialization efforts.

Total raised

$9M

Funding rounds

5

Latest round

Equity

Latest activity

Jun 2025